Orexigen Therapeutics, Inc. (OREX) Set to Announce Earnings on Wednesday
Orexigen Therapeutics, Inc. (NASDAQ:OREX) is scheduled to post its quarterly earnings results after the market closes on Wednesday, November 1st. Analysts expect Orexigen Therapeutics to post earnings of ($2.13) per share for the quarter.
Orexigen Therapeutics (NASDAQ:OREX) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, beating the consensus estimate of ($2.40) by $0.58. Orexigen Therapeutics had a negative return on equity of 824.15% and a negative net margin of 120.77%. The company had revenue of $23.36 million for the quarter, compared to analyst estimates of $20.00 million. During the same period in the prior year, the company posted ($1.73) EPS. The company’s revenue was up 199.9% compared to the same quarter last year. On average, analysts expect Orexigen Therapeutics to post $-10.77 EPS for the current fiscal year and $-6.5 EPS for the next fiscal year.
Shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) opened at 1.70 on Wednesday. Orexigen Therapeutics, Inc. has a 1-year low of $1.65 and a 1-year high of $5.70. The stock has a 50 day moving average price of $2.10 and a 200 day moving average price of $2.63. The company’s market capitalization is $26.23 million.
ILLEGAL ACTIVITY NOTICE: “Orexigen Therapeutics, Inc. (OREX) Set to Announce Earnings on Wednesday” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/25/orexigen-therapeutics-inc-orex-set-to-announce-earnings-on-wednesday.html.
OREX has been the topic of several recent research reports. ValuEngine raised shares of Orexigen Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 11th. Zacks Investment Research raised shares of Orexigen Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Receive News & Ratings for Orexigen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.